1. What is the best approach to reducing birth defects associated with isotretinoin?;Abroms;PLoS Med,2006
2. US. Food and Drug Administration. iPLEDGE update. 2006. Available at: https://www.ipledgeprogram.com/default.aspx. Accessed December 2010.
3. Shin J, Cheetham TC, Wong L, Niu F, Kass E, Yoshinaga MA, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol doi:10.1016/j.jaad.2010.09.017. Published online May 12, 2011.
4. Huber MH. Review of data from SMART program. FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting. 2004. February 26–27, 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm. Accessed December 2010.
5. US. Food and Drug Administration. 2007 Drug Safety and Risk Management Advisory Committee, Dermatologic and Ophthalmic Drugs Advisory Committee. Briefing Document. IPLEDGE year one Update. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4311b1-02-ipledge.pdf. Accessed December 2010.